Ticagrelor sustained release (Synokem Pharmaceuticals)

替格瑞洛缓释片 (Synokem Pharmaceuticals)

Report date: 2024/04/29 17:39:37

Base Information

Drug NameTicagrelor sustained release (Synokem Pharmaceuticals)
Drug Alias NameTicagrelor SR
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsMyocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSynokem Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMyocardial Infarction
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A